Abstract
Objective In recent years, high stone recurrence and biliary restenosis rates in hepatolithiasis patients have been confirmed to be closely related to chronic proliferative cholangitis（PC）.Since PC is a kind of chronic proliferative disease, we designed this study to investigate the feasibility and effectiveness of applying PCNA shRNA to inhibit the hyperplasia and lithogenic potentiality of PC and to explore a new treatment approach for the prevention of stone recurrence and biliary restenosis.Methods The common bile duct of a PC animal model was given an intralumenal administration of 0.5 ml of PCNA shRNA to investigate its influence on PC.Results The PCNA shRNA could efficiently inhibit the hyperplasia of the biliary epithelium, submucosal gland, and collagen fiber by inhibiting mRNA or protein expressions of PCNA and Procollagen Ⅲ, thus showing promise to control or reverse PC and its secondary biliary stricture.In addition, it could inhibit the lithogenic potentiality of PC by inhibiting the expression of mucin 5AC.Conclusion PCNA shRNA treatment might achieve the effect of controlling or reversing the PC and its subsequent biliary stricture and concurrently assist in preventing the recurrence of intrahepatic stone. Key words: Cholelithiasis; Proliferative cholangitis; Recurrence; Biliary duct restenosis; PCNA
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
